Full Press Release Details
Blog Post
| July 11, 2024
Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115
Read More
Previous Article
Next Article
Blog Navigation
VANI Positive Sentiment
Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115
Key Takeaway: Vivani Medical has announced updates regarding its clinical development plans for NPM-115, a miniature, long-term GLP-1 obesity implant. The program aims to address obesity through innovative technology. The company's focus on this area reflects a commitment to improving treatment options for patients.
Price reaction · baseline $1.25 (2024-07-10 close) · hit pre-market · clean, no other VANI news in the window
day 0 close
+5.6%
day 1
+7.2%
day 3 · peak
+8%
Market Sentiment Analysis
POSITIVE FACTORS
- Vivani Medical is advancing its clinical development plans.
- The NPM-115 program targets obesity with a novel GLP-1 implant.
- The miniature design may enhance patient compliance.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceCash runway
~10 mo
Medium dilution risk
Lead asset
Semaglutide
Phase 1 · Obesity & Overweight
Frequently Asked Questions
What is NPM-115?
NPM-115 is a miniature, long-term GLP-1 obesity implant developed by Vivani Medical.
What are the goals of the NPM-115 program?
The program aims to provide innovative treatment options for obesity.
How does the NPM-115 implant work?
The implant is designed to deliver GLP-1, a hormone that helps regulate appetite.
What recent updates has Vivani Medical provided?
Vivani Medical has shared updates on its clinical development plans for NPM-115.